Crystalline forms of antidiabetic compounds
    1.
    发明授权
    Crystalline forms of antidiabetic compounds 失效
    抗糖尿病化合物的结晶形式

    公开(公告)号:US07683092B2

    公开(公告)日:2010-03-23

    申请号:US11885842

    申请日:2006-03-10

    IPC分类号: A61K31/404 C07D209/18

    CPC分类号: C07D209/12

    摘要: Novel crystalline forms of two indole compounds connected to phenoxyalkylcarboxylic acid groups are selective PPAR gamma partial agonists that are useful in the treatment of type 2 diabetes, hyperglycemia, obesity, dyslipidemia, and the metabolic syndrome. The novel crystal forms include a crystalline free acid dihydrate and crystalline free acid anhydrate of one compound and several crystalline forms of the free acid and the sodium salt of the second compound. The invention also relates to pharmaceutical compositions comprising these novel crystal forms, processes to prepare the crystal forms and their pharmaceutical compositions, and uses of the crystal forms in the treatment of type 2 diabetes and other PPAR gamma modulated diseases.

    摘要翻译: 与苯氧基烷基羧酸基团连接的两个吲哚化合物的新结晶形式是可用于治疗2型糖尿病,高血糖症,肥胖症,血脂异常和代谢综合征的选择性PPARγ部分激动剂。 新型晶体形式包括一种化合物的结晶游离酸二水合物和结晶游离酸酐,以及第二化合物的游离酸和钠盐的几种结晶形式。 本发明还涉及包含这些新晶体形式的药物组合物,制备晶体形式的方法及其药物组合物,以及晶型用于治疗2型糖尿病和其它PPARγ调节疾病的用途。

    Novel Crystalline Forms of Antidiabetic Compounds
    2.
    发明申请
    Novel Crystalline Forms of Antidiabetic Compounds 失效
    抗糖尿病化合物的新型结晶形式

    公开(公告)号:US20080221198A1

    公开(公告)日:2008-09-11

    申请号:US11885842

    申请日:2006-03-10

    CPC分类号: C07D209/12

    摘要: Novel crystalline forms of two indole compounds connected to phenoxyalkylcarboxylic acid groups are selective PPAR gamma partial agonists that are useful in the treatment of type 2 diabetes, hyperglycemia, obesity, dyslipidemia, and the metabolic syndrome. The novel crystal forms include a crystalline free acid dihydrate and crystalline free acid anhydrate of one compound and several crystalline forms of the free acid and the sodium salt of the second compound. The invention also relates to pharmaceutical compositions comprising these novel crystal forms, processes to prepare the crystal forms and their pharmaceutical compositions, and uses of the crystal forms in the treatment of type 2 diabetes and other PPAR gamma modulated diseases.

    摘要翻译: 与苯氧基烷基羧酸基团连接的两个吲哚化合物的新结晶形式是可用于治疗2型糖尿病,高血糖症,肥胖症,血脂异常和代谢综合征的选择性PPARγ部分激动剂。 新型晶体形式包括一种化合物的结晶游离酸二水合物和结晶游离酸酐,以及第二化合物的游离酸和钠盐的几种结晶形式。 本发明还涉及包含这些新晶体形式的药物组合物,制备晶体形式的方法及其药物组合物,以及晶型用于治疗2型糖尿病和其它PPARγ调节疾病的用途。

    NOVEL CRYSTALLINE SALT FORM OF AN ANTIDIABETIC COMPOUND
    3.
    发明申请
    NOVEL CRYSTALLINE SALT FORM OF AN ANTIDIABETIC COMPOUND 有权
    新型水溶性盐酸盐形式

    公开(公告)号:US20100056580A1

    公开(公告)日:2010-03-04

    申请号:US12529202

    申请日:2008-02-28

    申请人: Aquiles E. Leyes

    发明人: Aquiles E. Leyes

    CPC分类号: C07D261/20

    摘要: A novel crystalline anhydrous toluenesulfonic acid salt form of a selective PPAR gamma partial agonist which has a fused bicyclic aromatic group attached to an oxypropanoic acid moiety is stable and non-hygroscopic. The crystalline salt form is useful for making pharmaceutical formulations for the treatment of type 2 diabetes, hyperglycemia, obesity, and dyslipidemia.

    摘要翻译: 具有与氧代丙酸部分连接的稠合双环芳族基团的选择性PPARγ部分激动剂的新型结晶无水甲苯磺酸盐形式是稳定且不吸湿的。 结晶盐形式可用于制备用于治疗2型糖尿病,高血糖症,肥胖症和血脂异常的药物制剂。

    Crystalline salt form of an antidiabetic compound
    4.
    发明授权
    Crystalline salt form of an antidiabetic compound 有权
    抗糖尿病化合物的结晶盐形式

    公开(公告)号:US08258161B2

    公开(公告)日:2012-09-04

    申请号:US12529202

    申请日:2008-02-28

    申请人: Aquiles E. Leyes

    发明人: Aquiles E. Leyes

    IPC分类号: A61K31/4439 C07D413/04

    CPC分类号: C07D261/20

    摘要: A novel crystalline anhydrous toluenesulfonic acid salt form of a selective PPAR gamma partial agonist which has a fused bicyclic aromatic group attached to an oxypropanoic acid moiety is stable and non-hygroscopic. The crystalline salt form is useful for making pharmaceutical formulations for the treatment of type 2 diabetes, hyperglycemia, obesity, and dyslipidemia.

    摘要翻译: 具有与氧代丙酸部分连接的稠合双环芳族基团的选择性PPARγ部分激动剂的新型结晶无水甲苯磺酸盐形式是稳定且不吸湿的。 结晶盐形式可用于制备用于治疗2型糖尿病,高血糖症,肥胖症和血脂异常的药物制剂。